Peptide Comparison
Palmitoyl Dipeptide-6 vs Rigin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Palmitoyl Dipeptide-6 and Rigin share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: minimal. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Palmitoyl Dipeptide-6 | Rigin | |
|---|---|---|
| Class | Cosmetic lipopeptide (retinol-mimic) | Cosmetic lipopeptide (anti-inflammatory) |
| Drug class | Dermatologic | Dermatologic |
| Mechanism | Activates retinoid-responsive genes without retinoid irritation | Suppresses IL-6 secretion by fibroblasts; reduces inflammaging |
| Route | Topical | Topical |
| Half-life | Topical | Topical |
| Dosage (research) | Topical 1-3% | Topical 2-4% |
| Evidence tier | Cosmetic Clinical Studies | Cosmetic Clinical Studies |
| Research depth | — | 31 indexed |
| Availability | Cosmetic | Cosmetic |
| Reported risks | Minimal | Minimal |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Palmitoyl Dipeptide-6 or Rigin?
Palmitoyl Dipeptide-6 and Rigin share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between Palmitoyl Dipeptide-6 and Rigin?
Palmitoyl Dipeptide-6 is classed as Cosmetic lipopeptide (retinol-mimic); Rigin is classed as Cosmetic lipopeptide (anti-inflammatory). Reported mechanism: Palmitoyl Dipeptide-6, Activates retinoid-responsive genes without retinoid irritation; Rigin, Suppresses IL-6 secretion by fibroblasts; reduces inflammaging. Reported half-life: Palmitoyl Dipeptide-6, Topical; Rigin, Topical. Routes in published studies: Palmitoyl Dipeptide-6, Topical; Rigin, Topical.
Which has stronger evidence, Palmitoyl Dipeptide-6 or Rigin?
Palmitoyl Dipeptide-6 and Rigin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Palmitoyl Dipeptide-6 is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page. Rigin is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 31 indexed studies.
Which is more accessible, Palmitoyl Dipeptide-6 or Rigin?
Neither Palmitoyl Dipeptide-6 nor Rigin is an FDA-approved drug. Catalog status: Palmitoyl Dipeptide-6, Cosmetic; Rigin, Cosmetic.
Are Palmitoyl Dipeptide-6 and Rigin ever combined?
Palmitoyl Dipeptide-6 and Rigin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…